Stratifind provides a pan‑cancer diagnostic platform that simultaneously performs whole‑transcriptome RNA sequencing and targeted DNA mutation profiling from a single tumor biopsy. Its proprietary bioinformatics pipeline generates cancer‑type‑agnostic prognostic scores and predictive biomarker reports, delivered through a secure web portal and compatible with EHR and trial‑selection workflows.
Funding
Funding not disclosed
Founders
Product
Problem
Oncologists often lack a single, comprehensive molecular assay that simultaneously evaluates both RNA expression and DNA alterations across multiple cancer types, making it difficult to generate accurate prognostic and predictive insights for individual patients.
Solution
Stratifind offers a pan‑cancer diagnostic platform that combines high‑throughput RNA sequencing with targeted DNA mutation profiling to deliver unified prognostic risk scores and predictive biomarker reports. The assay is designed to work with standard tumor biopsy material and generates results in a clinically actionable timeframe. Integrated bioinformatics pipelines translate raw sequencing data into validated outcome models that inform treatment selection and trial eligibility. Results are delivered through a secure web portal with customizable reports that can be incorporated into electronic health records and multidisciplinary tumor board discussions.
Target Audience
Primary customers are oncology physicians, molecular pathology laboratories, and pharmaceutical companies conducting precision‑medicine trials across solid tumor indications.
Features
- Simultaneous whole‑transcriptome RNA sequencing and targeted DNA panel analysis from a single sample
- Proprietary algorithms that produce cancer‑type‑agnostic prognostic scores and therapy‑response predictions
- Cloud‑based analytics pipeline with automated quality control, variant calling, and expression quantification
- Clinician‑focused report format including risk stratification, actionable mutations, and recommended therapeutic options
- API and HL7/FHIR compatibility for seamless integration with hospital information systems and EHRs
- Compliance with CLIA and ISO standards for clinical laboratory use